NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STEGLUJAN is a fixed-dose oral combination tablet containing ertugliflozin (SGLT2 inhibitor) and sitagliptin (DPP-4 inhibitor) approved in December 2017. It is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise. The combination works by dual mechanism: ertugliflozin increases urinary glucose excretion while sitagliptin enhances incretin-mediated insulin secretion.
$0.001BPart D
Peak4.5 years to LOEProduct is in peak lifecycle phase with modest Part D footprint (1,478 claims, 2023), indicating stable but not high-volume commercial activity requiring focused market penetration efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Started Apr 2014
1,233 enrolled
Type 2 Diabetes Mellitus
Why This Matters for Your Career
Worked on STEGLUJAN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.